Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Get Free Report) CEO Richard Townsend sold 3,295 shares of the business’s stock in a transaction dated Tuesday, November 17th. The stock was sold at an average price of $3.26, for a total value of $10,741.70. Following the transaction, the chief executive officer directly owned 373,483 shares of the company’s stock, valued at approximately $1,217,554.58. This represents a 0.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Lexeo Therapeutics Stock Performance
LXEO stock opened at $2.95 on Thursday. The company’s 50 day moving average price is $3.28 and its 200 day moving average price is $4.94. Lexeo Therapeutics, Inc. has a fifty-two week low of $2.55 and a fifty-two week high of $10.99.
Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) last issued its earnings results on Monday, November 16th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.11). Equities analysts anticipate that Lexeo Therapeutics, Inc. will post -1.22 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Lexeo Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc acquired a new position in Lexeo Therapeutics in the second quarter valued at $32,000. Signaturefd LLC grew its holdings in shares of Lexeo Therapeutics by 5,159.1% during the third quarter. Signaturefd LLC now owns 8,362 shares of the company’s stock worth $28,000 after purchasing an additional 8,203 shares during the last quarter. Lighthouse Investment Partners LLC purchased a new position in shares of Lexeo Therapeutics during the third quarter worth about $39,000. Abel Hall LLC acquired a new stake in shares of Lexeo Therapeutics during the third quarter worth about $43,000. Finally, Spark Investment Management LLC acquired a new stake in shares of Lexeo Therapeutics during the second quarter worth about $70,000. 60.67% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of equities research analysts have recently weighed in on LXEO shares. Wall Street Zen lowered shares of Lexeo Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, November 14th. Leerink Partners reiterated an “outperform” rating and set a $15.00 target price on shares of Lexeo Therapeutics in a research note on Wednesday, September 23rd. Raymond James Financial reissued a “strong-buy” rating on shares of Lexeo Therapeutics in a report on Monday. Cantor Fitzgerald restated an “overweight” rating on shares of Lexeo Therapeutics in a research note on Thursday, November 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexeo Therapeutics in a report on Wednesday, November 11th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $16.43.
View Our Latest Research Report on Lexeo Therapeutics
About Lexeo Therapeutics
Lexeo Therapeutics, Inc. is a clinical-stage biotechnology company developing gene therapies for inherited cardiovascular and other serious diseases. Its research focuses on using genetic medicines to address conditions caused by specific gene mutations. The company’s investigational programs include LX2006, a gene therapy being studied for Friedreich ataxia cardiomyopathy, and other candidates targeting genetically defined heart diseases. These therapies remain in development and are not established commercial products.
Featured Articles
- Five stocks we like better than Lexeo Therapeutics
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
